Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap219.91M
Enterprise Value9.07M
ARCT
(NASDAQ)Arcturus Therapeutics Holdings Inc.
$8.03-- (--)
Loading... - Market loading
Arcturus Therapeutics Holdings (ARCT) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)3.56
Forward Price/Sales5.09
Price/Book (mrq)1.00
Price/Tangible Book (mrq)1.00
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue0.15
EV/Earnings-0.14
EV/EBITDA-0.12
EV/EBIT-0.12
EV/FCF-0.12
Stock Price
Current price, 52-week range, and moving averages
Current Price$8.03
1-Day Change1.68%
52-Week High$24.17
52-Week Low$5.85
52-Week Change-16.75%
YTD Change25.60%
1-Year Change-23.04%
50-Day MA$7.37
200-Day MA$11.51
Avg Volume (30 day)504.75K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding27.39M
Book Value per Share$7.81
Net Cash per Share$8.28
FCF per Share$-2.73
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$15.15
Target Upside/Downside88.67%
Analyst ConsensusBuy
Analyst Count12
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin116.22%
EBITDA Margin (ttm)-123.95%
EBIT Margin (ttm)-124.28%
Operating Margin (ttm)-124.27%
Pretax Margin (ttm)-109.06%
Profit Margin (ttm)-109.06%
FCF Margin (ttm)-123.89%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-30.74%
Return on Assets (ttm)-24.26%
Return on Invested Capital (ttm)-733.47%
Return on Capital Employed (ttm)-31.93%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue60.32M
Gross Profit70.10M
Operating Income-74.95M
Pretax Income-65.78M
Net Income-65.78M
EBITDA-74.77M
EBIT-74.96M
Diluted EPS$-2.40
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-74.27M
Capital Expenditures455.66K
Free Cash Flow-74.73M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth-51.43%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)271.15M
Cash & Securities (mrq)230.91M
Net Cash (mrq)226.69M
Net Cash per Share$8.28
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)25.00M
Working Capital (mrq)205.07M
Total Equity (mrq)213.99M
Book Value per Share$7.81
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)6.64
Quick Ratio (mrq)6.64
Debt/Equity (mrq)0.12
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-30.60%
FCF Yield-34.76%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-0.18
Piotroski F-Score4/9
Frequently Asked Questions About Arcturus Therapeutics Holdings Statistics
What are the key financial metrics for ARCT?
Arcturus Therapeutics Holdings Inc. (ARCT) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is ARCT's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Arcturus Therapeutics Holdings is overvalued or undervalued.
How do I read ARCT's profitability ratios?
Arcturus Therapeutics Holdings's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do ARCT's debt ratios indicate?
The financial health section shows Arcturus Therapeutics Holdings's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is ARCT's dividend analysis?
The dividend section covers Arcturus Therapeutics Holdings's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.